Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis

Autor: I. Fell, Esther von Stebut, Elise Langer, Detlef Becker, Stephan Grabbe, Gunda Seemann, Martin Seemann, Joachim Saloga
Rok vydání: 2011
Předmět:
Male
Skin Physiology
Anatomy and Physiology
Light
medicine.medical_treatment
lcsh:Medicine
Pediatric Dermatology
Antigen Processing and Recognition
Atopic Dermatitis
Disease
Pediatrics
Quality of life
Young adult
lcsh:Science
Skin
Multidisciplinary
medicine.diagnostic_test
T Cells
Allergy and Hypersensitivity
Physics
Electromagnetic Radiation
Photodermatology and Skin Aging
Immunosuppression
Atopic dermatitis
Middle Aged
medicine.anatomical_structure
Treatment Outcome
Patient Satisfaction
Observational Studies
Medicine
Female
Whole-Body Irradiation
Research Article
Adult
medicine.medical_specialty
Langerhans cell
Clinical Research Design
Immune Cells
Immunology
Color
Dermatology
Dermatitis
Atopic
Young Adult
Ultraviolet Radiation
Biopsy
medicine
Humans
Serologic Tests
Biology
business.industry
lcsh:R
medicine.disease
Clinical trial
Immune System
Chronic Disease
Quality of Life
lcsh:Q
Clinical Immunology
business
Zdroj: PLoS ONE
PLoS ONE, Vol 6, Iss 6, p e20566 (2011)
ISSN: 1932-6203
Popis: Background Therapy of atopic dermatitis (AD) relies on immunosuppression and/or UV irradiation. Here, we assessed clinical efficacy and histopathological alterations induced by blue light-treatment of AD within an observational, non-interventional study. Methodology/Principal Findings 36 patients with severe, chronic AD resisting long term disease control with local corticosteroids were included. Treatment consisted of one cycle of 5 consecutive blue light-irradiations (28.9 J/cm2). Patients were instructed to ask for treatment upon disease exacerbation despite interval therapy with topical corticosteroids. The majority of patients noted first improvements after 2–3 cycles. The EASI score was improved by 41% and 54% after 3 and 6 months, respectively (p≤0.005, and p≤0.002). Significant improvement of pruritus, sleep and life quality was noted especially after 6 months. Also, frequency and intensity of disease exacerbations and the usage of topical corticosteroids was reduced. Finally, immunohistochemistry of skin biopsies obtained at baseline and after 5 and 15 days revealed that, unlike UV light, blue light-treatment did not induce Langerhans cell or T cell depletion from skin. Conclusions/Significance Blue light-irradiation may represent a suitable treatment option for AD providing long term control of disease. Future studies with larger patient cohorts within a randomized, placebo-controlled clinical trial are required to confirm this observation.
Databáze: OpenAIRE
Externí odkaz: